SAN RAMON, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Odyssey Thera, Inc. announced today that Hugh Y. Rienhoff, Jr., M.D. has joined the Company’s Board of Directors. Dr. Rienhoff brings both venture investor and life science entrepreneurial experience to the Board of Odyssey Thera.
Dr. Rienhoff Jr. is an entrepreneur who in 1998 founded and was CEO of DNA Sciences (originally Kiva Genetics), a company focused on the discovery and development of human genetic diagnostics. Before founding DNA Sciences, he was a Director of Abingworth Management Ltd., where he ran the US operation for the London-based venture capital firm. Prior to Abingworth, he was a Partner at New Enterprise Associates, a venture investment firm based in Menlo Park, California and Baltimore, Maryland. Dr. Rienhoff was a founding director of Healtheon (HLTH), Aurora BioSciences (ABSC), and oversaw investments in many life science and biotechnology companies including Microcide (MCDE), Geltex (GLTX), and Anadys (ANDS). He currently serves on the boards of Peptimmune, Hydra Biosciences, GeneEd and DataHooks. Dr. Rienhoff was previously a member of the faculty in the Department of Molecular Biology and Genetics at the Johns Hopkins University School of Medicine. He trained in mathematics and medicine at Harvard and the Johns Hopkins University, where he received a Doctor of Medicine degree. He received a Bachelor of Arts degree with honors in Biology and English Literature from Williams College.
“Hugh brings a tremendous depth of experience to Odyssey Thera,” said John Westwick, Odyssey Thera President and CSO. “He has a proven track record of working closely with management teams to maximize the potential of cutting-edge technology companies. We’re confident that Hugh can help us build on our recent scientific and business achievements.” Dr. Rienhoff said, “Odyssey has begun to realize its great potential and I am privileged to be a member of the team.”
About Odyssey Thera
Odyssey Thera, Inc. is a privately held biotechnology company that is pioneering a pathway-based approach to drug discovery. The use of human cells instead of isolated proteins aids in the identification of drug leads with desirable profiles, and enables early attrition of compounds with unintended effects in human cells. The company has created a comprehensive strategy for cellular systems biology and drug discovery, and is utilizing this capability both for the benefit of its pharmaceutical partners and to identify small molecules that block key cancer pathways. Visit Odyssey Thera’s website at http://www.odysseythera.com .
Odyssey Thera, Inc.
CONTACT: John K. Westwick, Ph.D., President and CSO of Odyssey Thera,Inc., +1-925-242-5011
Web site: http://www.odysseythera.com/
